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Abstract 
Transdermal iontophoresis is a method where the movement of ionic drugs (and 
sometimes also neutral drug molecules) across skin is enhanced using an externally 
applied potential difference. Iontophoretic devices contain three distinct components; 1) 
the drug reservoir which contains one electrode, the polarity chosen depends on the 
charge of the drug, 2) the return electrode and 3) the electronic controller. In this study 
ion-exchange fibers were investigated as a drug reservoir material for iontophoretic 
device.  
The parameters affecting the drug release from the ion-exchange fibers without 
applied current were studied experimentally and theoretically modeled using five model 
drugs and four different ion-exchange fibers. It was found that lipophilic drugs were 
retained more strongly and for longer in the fibers than hydrophilic drugs. The 
hydrophilic drugs were also released more readily from fibers containing strong ion-
exchange groups, whereas the lipophilic drugs attached more strongly to strong ion-
exchange groups and released more easily from the weak ion-exchange groups. The salt 
concentration and the choice of the salt also had an effect; when using equimolar amounts 
of sodium chloride at lower salt concentrations, more drug was released. Incorporation of 
calcium chloride in the bathing solution increased considerably both the drug release rate 
and the total amount of drug released when compared to sodium chloride alone. 
The drug release from the fibers were studied in vitro and in vivo using 
iontophoresis. Due to significantly different release properties, tacrine and metoprolol 
were chosen for screening of their suitability for this kind of iontophoretic system, using 
an in-house designed in vitro cell. It was found that the rate of tacrine release from the 
device could be controlled by adjusting the salt concentration and the current density 
used but the rate of metoprolol release could not be controlled this way. A semi-
quantitative and pragmatic interpretation of the results also showed that it should be 
possible to manufacture a transdermal iontophoretic patch to delivery tacrine. It was also 
determined in vivo that clinically relevant plasma concentrations of tacrine could be 
achieved in a human volunteer using an in-house designed and manufactured 
iontophoretic transdermal drug delivery patch. 
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1. Introduction 
The benefits of using transdermal drug delivery include improved systemic 
bioavailability resulting from bypassing the first pass metabolism. Variables due to oral 
administration, such as pH, the presence of food or enzymes and transit times can all be 
eliminated. Transdermal drug delivery also allows fast interruption of the treatment in the 
case of adversed effects.  
In the development of new transdermal drug delivery devices the aim is to obtain 
controlled, predictable and reproducible release of drugs into the blood stream of the 
patient. The transdermal device acts as a drug reservoir and controls the rate of drug 
transfer. When the transdermal drug flux is controlled by the device instead of the skin, 
delivery of the drug is more reproducible leading to smaller inter- and intrasubject 
variations, since the drug release from the device can be controlled more accurately than 
the permeability of the skin.1 
One potential drug reservoir is to bind the drug within an ion-exchange system. 
Charged drugs remain bound to the ion-exchange groups of the ion-exchange matrix until 
released by mobile ions, e.g. sodium, Na+. The release rate of the drug can be controlled 
with the current, the mobile ion concentration and pH.2-4 The complexation of the drugs 
with ion-exchange resins has shown promise for achieving controlled drug release,5,6 
drug delivery7 and also to enhance drug stability during storage.6,8 
This project has studied the properties of ion-exchange fibers as a drug reservoir 
for iontophoretic transdermal drug delivery using several model drugs. An iontophoretic 
patch was developed in order to conduct a clinical study on tacrine, a reversible 
cholinesterase inhibitor used for treating patients with Alzheimer’s disease, to determine 
whether therapeutically relevant plasma concentrations could be achieved in healthy 
human volunteers. 
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2. Background 
2.1 An overview of iontophoresis 
Iontophoresis is a method where the movement of ions across a membrane is 
enhanced using an externally applied potential difference. When the membrane under 
consideration is skin, the method is called transdermal iontophoresis. 
The principal barrier to the transport of molecules into and across the skin is the 
stratum corneum (SC), this is the uppermost layer of the epidermis with a thickness of 
between 10 and 100 µm. The SC consists of several layers of corneocytes (anucleate 
keratin filled cells) inlaid in a lipid matrix, a continuous medium through the SC, 
arranged mainly in bilayers.9,10 The intercellular lipids consist of approximately equal 
quantities of ceramides, cholesterol and free fatty acids.11 
Percutaneous absorption may take place simultaneously by any combination of 
the three main pathways;11-14 
· The intercellular (paracellular) pathway between the corneocytes along the lamellar 
lipids. 
· The intracellular (transcellular) pathway through the cells.  
· The appendageal (shunt) pathway via hair follicles, sweat ducts and secretary glands. 
Ions prefer the route of the least electrical resistance, in the SC this is believed to be 
via the pores. Some investigations indicate that these pores are sweat glands,15,16 others 
that transport occurs through both sweat glands and hair follicles. 17-19 
The physico-chemical properties of the molecule have an effect on the 
contribution of the follicular and non-follicular routes of penetration. Hydrophilic 
molecules tend to localize in the hair follicles, whereas lipophilic molecules are mostly 
distributed in the lipid intercellular regions of the stratum corneum and the lipid 
membranes of the epidermal keratinocytes.20 
Since passive transdermal permeation of the majority of drugs needs enhancement 
to achieve clinically relevant plasma concentrations, both chemical and physical 
enhancement methods have been developed. Iontophoresis is one of the physical 
methods. 
In transdermal iontophoresis, cationic or neutral therapeutic agents are placed 
under an anode, or anionic therapeutic agents under a cathode. When a low voltage and 
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low current density is applied, according to simple electrorepulsion, ions are repelled into 
and through the skin. Cationic drugs are driven into and through the skin by the anode 
(active electrode), which also exctracts anions from the tissue underneath the skin into the 
anode. At the cathode (return electrode) anionic buffer ions are driven into the skin and 
cations from the tissue are extracted into the cathode. See figure 1. 
 
 
Figure 1. Schematic representation of the iontophoretic drug delivery. (Modified from ref. 21) 
 
It is also possible to include an additional charged drug in the return electrode to 
be delivered simultaneously or to use a mixture of drugs in the active electrode to 
enhance the desired effect or to increase skin permeation, depending on which 
drugs/molecules are used.22-24 
More formally, transdermal iontophoresis should be called electrically assisted 
transdermal delivery. There are three major enhancing mechanisms for drug flux through 
the skin, of which iontophoresis (also known as electrorepulsion, or electromigration, or 
the Nernst-Planck effect) is just one. The other mechanisms are: electroosmotic flow25-29 
and current induced increase in skin permeation, also known as damage effect.30 
Electroosmotic flow is a flux of bulk fluid induced by a voltage difference across 
a charged membrane; it is always in the same direction as the flow of counter ions. Since 
human skin is negatively charged under physiological conditions, the counter ions are 
cations and the electroosmotic flow is thus from anode to cathode. Therefore the cathodic 
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delivery of anions is hindered and the anodic delivery of cations is assisted by 
electroosmosis. 
The improved movement of neutral molecules under iontophoresis is based on 
electroosmosis. Ions are influenced by all of the above mechanisms so that 
electroosmosis has a positive contribution to the transport of cations and a negative 
contribution to the transport of anions under normal physiological conditions. The impact 
of electroosmosis on ion transfer increases with the size of the ion.31 The contribution of 
electroosmosis can be so significant that the delivery of large anions from the anodic 
compartment can be more efficient than delivery from the cathode, this is called “wrong–
way iontophoresis”.27 
The electrorepulsion effect gives the largest enhancement to the flux of small 
lipophilic cations.32 When the concentration of the ionic drug is very high, so that the 
drug carries most of the current, electroosmotic flow has a very small effect on the drug 
flux.25 
Transdermal iontophoresis has been used for both local and systemic drug 
delivery. Applications include local delivery of anesthetics (e.g. lidocaine),33 steroids and 
retinoids to treat acne scarring,34 for the relief of palmar and plantar hyperhidrosis35 and 
the administration of pilocarpine in the diagnosis of cystic fibrosis.36-38 Other applications 
of transdermal iontophoresis include the administration of anti-inflammatory drugs e.g. 
ketoprofen,39 into subcutaneous tissues and joints. Iontophoretic delivery of several 
systemic drugs are still under investigation these include the analgesic fentanyl,40 a 
reversible cholinesterase inhibitor tacrineIII and several formulations of insulin.41-46 
The symmetrical nature of iontophoresis, where ions are driven both into and out 
of the body, has been utilized for extracting information from the body without the need 
for blood sampling. A reverse iontophoresis device has already been introduced for 
glucose monitoring in patients with diabetes.47-50 Reverse iontophoresis has also been 
tested for monitoring caffeine and theophylline in premature neonates.51 Another possible 
use for reverse iontophoresis is in detecting phenylalanine for the diagnosis of 
phenylketonuria, a potentially fatal metabolic disease in infants.52,53 
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2.2 Iontophoretic devices 
2.2.1 In vitro devices 
Several types of permeation cell have been used to study the feasibility of drug 
molecules for iontophoretic transport. One experimental arrangement is the side-by-side 
diffusion cell, where a skin sample is sandwiched between two half cells. The drug under 
examination in solution and the electrode are placed facing the SC side of the skin in one 
half of the cell, which acts as the drug reservoir, whereas, the other half of the cell acts as 
the return reservoir containing an electrode in a conducting solution.26,54 Sometimes a 
buffer solution is added to compartments in order to simulate physiological conditions. A 
four electrode system has been used in order to measure the potential drop across the 
skin,55 Masada et al. developed this idea further to maintain the potential drop across the 
skin.56 
Bellantone et al. produced a cell design where the two electrodes are placed above 
the skin simulating the in vivo conditions.57 A large skin membrane is used to overlap the 
edges of the diffusion cell and the electrode is attached to the SC side of the skin and the 
second electrode is placed in the drug reservoir. 
Glikfeld et al. modified the Franz diffusion cell, where the half cells are on top of 
each other and the skin placed horizontally between them.58 Furthermore, in the upper 
half of the cell, a glass wall separates the two electrode compartments, the current thus 
flows from the active electrode compartment across the skin into the receptor 
compartment and then back to the upper cell half but now to the return compartment. 
Although both cell designs have offered reliable data, the advantage of the cell 
with electrodes on the same side of the SC is that it offers the possibility to study lateral 
transport and examine iontophoresis for subcutaneous and non-invasive sampling.59 
Junginger used a three-chamber continuous flow-through transport cell in his in-
vitro modelling of apomorphine.60 This construction had two continuously stirred outer 
chambers which contained electrodes. Between these two chambers lay the acceptor 
chamber separated from the outer chambers by the SC and the supporting dialysis 
membrane, this chamber had a continuous flow of buffer solution. The advantage of the 
flow-through cell was the possibility to automate the set-up, which allows fast collection 
of data. The disadvantage was that experimental variables (volume, sampling interval and 
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flow-rate) had an effect on the value of the apparent flux which may deviate from the 
intrinsic flux through the skin. 
In the present studies an in-house designed test cell has been used, a schematic 
representation of which is shown in figure 2.61 In this test system both SC and porous 
membranes can be used depending upon whether transdermal iontophoresis or just drug 
release from the patch formula is studied. The patch type structure of the cell makes it 
practical for testing different kinds of matrix as well as drug and salt solution 
combinations. In this work the cell was used for testing ion-exchange fibers as a matrix 
for ionic drugs. 
 
Figure 2. In vitro iontophoretic cell. 1) return chamber 2) lid 3) Ag/AgCl electrode 4) magnetic stirrer 5) 
stratum corneum or porous membrane 6) donor chamber 7) NafionÒ membrane 8) salt solution chamber 9) 
Ag/AgCl electrode. 
 
2.2.2 In vivo devices  
Iontophoretic devices contain three distinct components; the drug reservoir, the 
return reservoir and the electronic controller. 
One way to classify iontophoretic controllers is by the drug delivery mode used. 
Direct current  (DC) mode systems are useful for acute conditions, as they give a constant 
intensity of direct current, resulting in continuous drug delivery. Pulsed direct current 
mode systems are applicable for chronic conditions reducing the risk of skin irritation. 
Some iontophoretic devices under different manufacturing stages are listed in table 1. 
2 
3 
1 4 5 6 7 8 
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Most commercial products use Ag/AgCl electrodes, the drug reservoir is usually 
aqueous and the filling material is often made of a biocompatible gel which matches the 
shape of the skin surface. In general, electrode gel materials can be divided into two 
types; the wet type, which has been used in most commercial systems and solid dry 
gels.31 
Wet type electrodes are often karaya gum based,31, 75 but the major problem with 
these electrodes is poor durability, which can lead in the worst case to exposure of the 
skin to the bare electrode. Also, they are quite expensive to manufacture and have 
tendency to irritate the skin. Dry hydrogels are simple and economic to manufacture and 
have firm electrical contacts, but are less conductive than the gels.76 Several filling 
materials under research including natural polymers and synthetic polymers are listed in 
table 2. 
The return reservoir contains saline solution to complete the electronic circuit. 
Additionally it is possible to include a charged drug in the return reservoir to be delivered 
simultaneously. Otherwise the electrode material is similar to the drug reservoir materials 
described above. 
A couple of novel systems have been reported: One uses a buffering system and 
bilayer design in which the electrode comprises of a mixture of electroconductive 
material, where the polymer functions as an electrode as well as a matrix to immobilize 
the competitive ions.77 In another novel work, Haga et al.78 utilized microfabrication 
technology; they developed photo-etched devices with efficient current distribution for 
transdermal iontophoretic drug delivery. 
Even though iontophoretic systems usually have a patch type formulation, this is 
not the only way to solve the problem. A pencil shaped system for topical delivery has 
been used to deliver antihistamines.79 In this application the drug is delivered in the style 
of an injection, the end with the anode gel carrier system is placed onto the skin and the 
circuit is completed by the patient’s finger at the cathode. However, for continuous drug 
delivery this is perhaps not the most practical solution. 
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Table 2. Materials tested for the drug reservoirs (or as a component of the reservoir material). 
Material tested Drug Type Author References 
Agar based hydrogels containing 
ion-exchange resins 
Nicotine Wet Conaghey et al 5, 6 
Chitosan  SNA (a) Wet Fang et al. 87 
Gelatin containing microemulsion 
based organogels  
Sodium salicylate Wet Kantaria et al. 80 
Carboxymethyl cellulose sodium 
(CMC) 
Enoxacin Wet Fang et al. 93 
Hydroxyethyl methacrylate 
hydrogel 
Gentamicin Wet Frucht-Pery et al. 81 
Hydroxypropylcellulose (HPC) SNA (a)  Fang et al. 87 
Hydroxypropyl methyl cellulose 
(HPMC)  
SNP (b), Diclofenac 
sodium, SNA, 
Enoxacin 
Wet Fang et al. 82, 83, 84, 
93  
Hydrophilic microporous 
membrane 
GHRP (c) Wet Ellens et al. 61 
Hydrophilic polyacrylate  SNA  Wet Fang et al. 87 
Ion-exchange fibers  Tacrine, Metoprolol 
 
 
Wet Jaskari et al. 
Vuorio et al. 
Murtomäki et al. 
I, III 
V 
85 
Karayagum/ glycerin / acrylamide  Metoprolol Wet Okabe et al. 86 
Methyl cellulose  SNP, SNA Wet Fang et al. 84, 87  
Pectin SNA Wet Fang et al. 87 
Poloxamer 407 Insulin, Arginine 
vasopressin 
Wet Panchagnula  
et al. 
88, 89 
Polyacrylamide (PAA) hydrogel  Insulin, Arginine 
vasopressin, Calcitonin 
Wet Banga et al. 90 
Polymer electrolytes 
(Polyethyleneoxide) 
Lidocaine(-HCl), 
Lithium Chloride 
Dry Sahota et al. 91, 92 
Polyvinylalcohol (PVA)  Enoxacin Wet Fang et al. 93 
Polyvinylpyrrolidine (PVP) 
hydrogels 
Enoxacin, SNA, 
Diclofenac sodium 
Wet Fang et al. 83, 87, 93 
(a) Sodium nonivamide acetate 
(b) Sodium nonivamide propionate 
(c) Growth hormone-releasing peptide (L-histidyl-D- tryptophyl -L-alanyl-L-tryptophyl-D-phenylalanyl-L-
lysinamide) 
 
 
3. Materials under research 
3.1 Ion-exchange fibers 
 All the fibers under investigation were manufactured by SmopTech Co. (Turku, 
Finland). Three different cation- and one anion- exchanger groups were used, these were 
radiation grafted onto the polyethylene backbone of the fibers. More detailed information 
about the fibers is presented in table 3. 
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Table 3. Ion-exchange fibers under investigation. 
Fiber Publication Ion-exchange groups Fiber material  Ion-exchange 
capacity (mmol g-1) 
SmopexÒ
-101 
I, II, IV -SO3H Poly(ethylene-g-styrene 
sulfonic acid) 
3.2 
SmopexÒ
-102 
I -V  -COOH Poly(ethylene-g-acrylic 
acid) 
8.0-9.7 
SmopexÒ
-107 
I, II  1:1 -SO3H and -COOH Poly(ethylene-g-acrylicacid-
co-vinyl sulphonic acid) 
8.0 
SmopexÒ
-108 
I -NH2 Amidoxime 3.4 
 
 The fibers were either woven into a cloth-like structure (I, II, III) or short strips of 
4 mm length (IV) or 2.3 mm length (V). Also, two commercial ion-exchange matrices 
containing carboxylate ion-exchange groups were tested in paper IV; Diaion WK100 ion-
exchange resin and Amberlite IRC-86 gel (both from Supelco, Bellefonte, PA, USA). 
 
3.2 Model drugs 
Tacrine (-HCl), propranolol (-HCl), metoprolol (-tartrate) and nadolol were 
obtained from Sigma (St. Louis, USA), sodium salicylate was from Aldrich-Chemie 
(Steinheim, Germany). In table 4, the physicochemical properties and molecular 
structures of the drugs studied are presented. 
Model drugs were chosen on the grounds of their physicochemical properties, 
such as lipophilicity; the higher the logP value the greater the lipophilicity. All of the 
drugs chosen had shown some potential for iontophoretic transdermal delivery.80, 86, 94, 95 
Tacrine was chosen for the in vivo test. It was hoped that using iontophoresis 
would minimize the difficulties associated with oral administration, such as low 
bioavailability, short elimination half-life,96 hepatotoxicity and peripheral cholinergic 
side effects.94 Additionally, it has been suggested that constant levels of tacrine in the 
brain may maximize the effect on memory enhancement and iontophoretic delivery may 
give more constant plasma concentration for prolonged time.94 
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Table 4. Physico-chemical properties of the drugs under investigation. 97, I 
Drug Structure 
Molecular 
weight 
(g mol-1) 
Dissociation 
constant (pKa) 
octanol/water 
partition 
coefficient (logP) 
Classification 
Tacrine 
 
 
198.27 9.8±0.2 (a) 3.30 (b) 
Anti-
cholinergic 
Propranolol 
 
 
259.35 9.45 3.56 b, 2.75 (c ) ß-blocker 
Metoprolol 
 
 
267.37 9.70 1.88 (b), 1.20 ( c) ß-blocker 
Nadolol 
 
 
309.41 9.39 0.71 (b) , 0.23 ( c) ß-blocker 
Sodium 
salicylate 
 
 
160.1 3.0 1.5 Keratolytic 
a) Our determination (I) 
b) Determined experimentally 96  
c) Calculated using CLOGP version 3.54. 96 
 
4. Results and Discussion 
4.1 An equilibrium study (II) 
 The cationic model drugs in this study were tacrine (-HCl), propranolol (-HCl) 
and nadolol, the cation-exchange fibers studied were Smopex® -101, -102 and -107. All 
of the fibers were in woven form. 
 The fibers were activated by soaking in 0.1 M NaCl or a 1:1 mixture of 0.1 M 
NaCl and 0.1 M NaOH solutions prior to use and then washed with MilliQ water 
(Millipore, France). The fibers were immersed in a 1 w-% drug solution for 24 hours so 
that drug solution was changed three times during the procedure (at the beginning of the 
N
NH2
OCH2-CHOH-CH2-NH-CH(CH)3
OCH2-CHOH-CH2-NH-CH(CH3)2
(CH2)2-OCH3
OH
OH
OCH2-CHOH-CH2-NH-C(CH3)3
OH
COONa
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immersion, after 3h and after 6h) and finally the fibers were washed with pure water to 
remove any excess unbound drug. 
  Drug release from the fibers was tested by placing the fibers in the electrolyte 
solution (0.0015, 0.015, 0.15 or 1.5 M NaCl and in the case of tacrine also 0.015 M 1:9, 
1:1 or 9:1 CaCl2 / NaCl solutions). The volume of the electrolyte solution was chosen so 
that each solution contained an equimolar amount of the salt as there was drug in the 
fiber. The electrolyte solutions were changed five times during a week (at 1, 2, 3, 4 and 7 
days). After every change of the electrolyte solution the fibers were washed with MilliQ 
water and the drug concentration was determined by HPLC from the combined solutions 
of electrolyte and washing water. 
 
4.1.1 Drug partition equilibrium 
 The cationic drug (D+) is released from the fiber by an ion-exchange mechanism, 
where sodium ions from the solution phase replace the drug ion in the fiber as follows. 
D+(fiber) + Na+(aq) « D+(aq) + Na+(fiber) 
The distribution of the drug between the fiber and the solution phases in the 
equilibrium arises from electrostatic and hydrophobic interactions, the former of which is 
measured by the electrical partition coefficient (Ke,d) 98, 99 
÷
ø
ö
ç
è
æ f-=
T
zexpK
R
F Dd
de,          (1) 
where zd represents the charge number, F is Faraday constant, R is the gas constant and T 
is the thermodynamic temperature. f-fºfD  is the Donnan potential, which is defined 
by the ion-exchange capacity of the fiber and the concentration and character of the 
external solution, the overbar denotes the fiber phase. In this case, where a cationic drug 
is in a cation exchanger zd > 0 and fD  < 0 resulting  Ke,d>1. 
 The chemical partition coefficient (Kc,d), defined in Eq. (2), measures the specific 
interactions of the drug with the fiber i.e. the tendency of the drug to get into the 
hydrophobic fiber,100 
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         (2) 
where m0d  is the standard chemical potential of the drug species. The decrease in free 
energy due to interactions between the drug and the fiber grows with the hydrophobicity 
of the drug, yielding a greater value of Kc,d (>1). In the case that the drug is hydrophilic 
Kc,d can be <1, since the water content of the fiber also has an effect on the value of Kc,d. 
 Combining these two coefficients results in the molar concentration ratio of the 
drug.99, 101 
KKK
c
c
dc,de,dp,
d
d ==          (3) 
This equation presents the Donnan equilibrium i.e. the electrochemical potential of the 
drug in the fiber phase and the external phase take the same value under equilibrium 
conditions. Since the drug concentration is comparatively low in both phases activity 
coefficients are not included in Eq. (3). 
 Table 5 represents the released amount of the drug from different fibers as a 
function of NaCl concentration. For the release rate of drugs from the fibers the 
lipophilicity scale tacrine »  propranolol > nadolol was valid for all fibers, the rate of 
drug release decreased with increasing lipophilicity. 
For the 101 fiber, the release rate of hydrophilic nadolol was over ten times higher 
than the release rate of lipophilic tacrine, whilst in the case of 102 fibers the difference in 
rates was only about factor of two. These results suggest that the specific interactions of 
the lipophilic drugs are stronger with sulphonic acid fibers than with the carboxylic acid 
fibers and vice versa for the hydrophilic drugs. This was also noted when the fibers were 
loaded with the drugs; propranolol and tacrine adsorbed more to the 101 fiber than to the 
102 fiber and again the opposite effect was observed for the nadolol. The same effect i.e. 
the drug is released faster from the carboxylic acid groups than from the sulphonic acid 
groups has also been observed in the case of resins.102 
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Table 5. The effect of the salt concentration and the fiber to total released amount of the drug (%) during 
one week test. Average ± standard deviation (N=3). 
Drug [NaCl] /  (moldm
-3) SmopexÒ-101 SmopexÒ-102 SmopexÒ-107 
Tacrine 0.0015  3.8 ± 1.0 8.7 ± 0.3 13.8 ± 1.2 
 0.015 4.4 ± 1.2 9.4 ± 2.1 14.0 ± 1.9 
 0.15 3.2 ± 0.3 7.5 ± 0.7 10.6 ± 0.7 
 1.5 1.8 ± 0.4 10.2 ± 2.0 10.0 ± 3.4 
Propranolol  0.0015  7.9 ± 0.1 13.8 ± 0.7 12.6 ± 1.2 
 0.015 5.4 ± 0.4 10.6 ± 0.3 8.1 ± 1.2 
 0.15 4.8 ± 0.6 9.4 ± 0.5 9.4 ± 0.6 
 1.5 3.3 ± 0.3 5.5 ± 0.6 7.5 ± 1.0 
Nadolol 0.0015  59.9 ± 5.3 16.5 ± 0.9 46.4 ± 2.0 
 0.015 51.4 ± 2.2  12.7 ± 0.4 27.9 ± 2.8 
 0.15 44.4 ± 3.7 11.3 ± 0.5  24.2 ± 1.1 
 1.5 43.0 ± 3.8 6.6 ± 0.7 22.7 ± 1.7 
 
The effect of drug concentration in the fibers to the release rate was also detected 
(in 102 fiber), when the drug content in the fibers increased it naturally lead to a greater 
amount of the drug released, but the fraction of the drug being released remained about 
the same. The same effect has also been detected in ion-exchange resins.6 
 
4.1.2 The effect of ionic strength 
 The volume V of the electrolyte solution was inversely proportional to its 
concentration, so that the number of moles of electrolyte cations used was the same in 
each experiment. 
Vcn 00 ++ =           (4) 
The limited amount of electrolyte in the partitioning equilibria gave the result that the 
drug release was influenced by both the electrostatic and volume effects. 
The molar concentration ratio of the electrolyte ions was mainly influenced by 
electrostatic interactions and so the partition coefficient for the electrolyte ions is simply  
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K zK
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where Ke = exp(F fD /RT) and zi is the charge number of species i.
 99, 101 Given that the 
drug solution is completely dissociated, the Donnan potential, fD , is defined by the 
electroneutrality conditions in the fiber and external solutions.98 Using the 
electroneutrality conditions in the fiber and external solution and eqs. (3) and (5) lead to 
the relationship 
( )( )[ ]
( )cc
Kcccccc
K
/
d
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dc,dd
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mm
e 2
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+
++++-
=
+
++       (6) 
where 
0
/ dmdm czzc =  is the concentration of ion-exchange groups bound to the fiber and 
zm is the charge number of the groups. 
 It is important to note that concentrations cd and c+ depend on Ke since the limited 
amount of the drug and external electrolyte ions requires that the following conditions are 
satisfied. 
VcVcn dd
0
d +=          (7a) 
VcVcn +++ +=
0          (7b) 
Also note from Eq.(6) that fD  = (RT/F)lnKe may become positive (i.e. Ke > 1) when Kc,d 
>>1. That is, the fiber might act as an anion-exchanger due to strong chemical 
interactions with the drug. 
 The experimental results showed that the effect of electrolyte concentration on the 
drug release rate was more profound on nadolol and propranolol, the drug release rate 
increased with decreasing concentration and increasing volume (Table 5). In the case of 
tacrine the trend was not as clear, possibly due to stronger specific interactions, which 
resulted in a low drug release rate. These results can be explained by considering Eq. (4) 
and the change in electrolyte volume with the concentration. The volume was one 
thousand times greater for the most dilute concentration compared to the most 
concentrated solution, which is bound to have an effect on the drug release as described 
in eqs. (7a) and (7b). First, the increasing electrolyte concentration decreases the Donnan 
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potential, (i.e. the electrostatic affinity between the drug and the fiber) leading to an 
increase in drug release. Second, a smaller external solution volume requires a very small 
amount of released drug to reach the equilibrium drug concentration in the external 
solution. From these experiments we can conclude that the latter of these competing 
effects is dominant. 
 The increase in drug release rate with increasing electrolyte concentration would 
be detected if the volume of the external solution were kept constant. This had been 
observed earlier with ion-exchange resins.5, 103 
 The release of tacrine was also studied with mixed solutions of NaCl and CaCl2 at 
fixed total concentrations to see if divalent Ca2+ ions had any effect on release rate. It was 
discovered that even 10 % CaCl2 had a considerable effect on the tacrine release rate, see 
Table 6. The release was enhanced from all the fibers, to a lesser extent for the 101 (from 
~4% to up to ~16 %) and substantially from 102 (from ~10% to up to ~100%) and 107 
(from ~15 % to up to ~100 %). Calcium ions are known to bind strongly with carboxylic 
groups at the pH used in these experiments, which explains the increased release rates 
from the fibers.104 
 
Table 6. Effect of Ca2+ fraction in the NaCl/CaCl electrolyte solution to tacrine release from the fibers. 
Average ± standard deviation (N=3). 
Ca2+ -% SmopexÒ-101 SmopexÒ-102 SmopexÒ-107 
10 13.6 ± 3.6 90.5 ± 14.4 91.8 ± 12.9 
50 13.7 ± 0.4 99.2 ± 3.6 95.7 ± 16.8 
90 15.9 ± 2.2  71.6 ± 23.8 102.8 ± 12.7 
 
The calcium chloride fraction also seemed to have an effect on the drug release 
rate; although the distribution of the results is rather large. Simply increasing the calcium 
chloride fraction decreases the Donnan potential, which lead to an increase in the drug 
amount of released. In the case of the 101 and 107 fibers the increase is due to the 
reduction of the effective charge of the fiber resulting from the formation of -[COOCa]+ 
groups which leads to a reverse of the effective charge of the fiber when the fraction of 
CaCl2 is 90 %. For lower fractions of CaCl2 the effective fixed charge does not reverse in 
sign but is so small that the fiber acts as an anion exchanger (i.e. Ke<1). In the case of the 
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102 fibers the trend of drug release increasing with the fraction of CaCl2 is reversed 
between 50 and 90 %. This is due to the increase of chloride ions with increasing fraction 
of CaCl2, which is equivalent to the increasing concentration of the electrolyte solution, 
thus it makes the Donnan potential closer to 1 which means a lower amount of drug 
released in the case where the fibers act as an anion exchanger. 
 
4.2 A transient study (IV) 
In this study the cationic model drugs were tacrine (-HCl), propranolol (-HCl), 
metoprolol (-tartrate) and nadolol, the ion-exchange fibers under investigation were 
Smopex® -101, -102 either in the woven form or 4 mm long staples. Also, commercially 
available ion-exchange resin (Diaion WK100) and gel (Amberlite IRC-86) containing 
carboxylate ion-exchange groups were tested. 
The ion-exchange material loaded with the drug was placed in the flow-cell. NaCl 
solution (0.15 M) was pumped through the cell at varying flow rates (0.1 - 5.0 cm3min-1). 
The resulting mixture of salt and drug was gathered using a fraction collector. Drug 
concentrations from the mixture were analysed by HPLC. 
 
4.2.1 Kinetics of ion-exchange  
 The ion-exchange mechanism in the case where a cationic drug (D+) is in the fiber 
and Na+ in the solution has three steps: (1) Na+ ions diffuse to the solid surface through 
the solution, (2) the Na+ ions diffuse inside the solid phase, (3) the chemical exchange 
reaction between the Na+ and D+ occurs in the ion-exchange groups. Finally, the D+ 
diffuses back into the solution through the same steps. The slowest step of these three is 
called the rate determining step (RDS). Depending upon which of steps 1, 2 or 3 is the 
RDS the reaction is called accordingly “liquid film diffusion controlled”, “particle 
diffusion controlled” or “chemical reaction controlled”. 
The equilibrium constant K for the ion-exchange reaction where the cationic drug 
is replaced in the fiber phase by sodium ion is defined by Eq. (8) 
cc
cc
P
PK
Nad
Nad
0
d
0
Na ==          (8) 
where P0 is the partition coefficient between the water and the fiber phase. 
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 The ion-exchange reaction is fast compared to the rate of diffusion and the 
Donnan equilibrium is assumed to be valid on the fiber,98 hence the kinetic problem is 
reduced to a transport problem. The Nernst-Planck equation is used in a unidimensional 
form to describe the molar flux density Ji of the ionic species i 
D
uc
xRT
F
cz
x
cj
i
i
ii
i
i d
d
d
d
-+=-
f         (9) 
where ji = Ji/Di, Di is the diffusion coefficient of i, x is the perpendicular distance from 
the fiber surface and u is the convective velocity of the solution.  
The solution of the equations in the diffusion boundary layer must satisfy the 
electroneutrality condition c2 = c1 + c3, where the subscripts 1, 2 and 3 denote Na+, Cl- 
and the ionic form of the drug respectively. To reduce the number of fitting parameters 
several approximations are introduced. First, the diffusion coefficients Di are given by 
values D1 = D2 = 2D3 = D. Second the Goldman constant electric field assumption is 
presented, the electric field in dimensionless form is marked by E, where E = -
(Fd /RT)d f /dx and d  is the diffusion boundary layer thickness. E must be evaluated 
from the open circuit condition I = F( S Ji) = 0. Also, the Peclet number 
AD
V
D
uPe
·
d=dº  is 
introduced and this conceals all the simplifying assumptions made ( A  is the effective 
surface area and 
·
V  is the volume flow). The Cl- ions are assumed to be completely 
excluded from the ion-exchange fiber, hence 002 =P  and J2 = 0. Now, when x = 0 and i = 
2, at the fiber solution interface, Eq. 9 gives 
EPeecc
-= s2b2           (10) 
where superscripts b and s denote the bulk aqueous phase and the interface, respectively 
and ( )02s2 cc =  and ( )d= cc 2b2 . 
To solve the flux equations for each component it was assumed that the flux 
density Ji is independent of position within each time interval D t (a quasi-stationary state 
assumption). Now the transport equations for Na+ and D+ can be solved similarly, solved 
for the flux densities they give 
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I = S iziDiji = 0 and the value of E can now be obtained from the numerical 
solution of 
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Dimensionless variables are now introduced for convenience, yk = ck / c0 , where 
c0 is the concentration of the feed solution. Also, the concentration of ionic species in the 
membrane is represented as dimensionless variables c/cy ii = . First, 11 13 =-= yy , 
0b3 =y  and 1
b
2
b
1 == yy . Also, when we assume that the kinetics of ion-exchange are very 
fast, the D+ bound to the fiber is immediately replaced by Na+, hence first 0s1 =y  
(diffusion is too slow to compensate for the amount of Na+ exchanged into the fiber). 
Electroneutrality must also be satisfied at the interface so Eq. (10) implies that first 
eyy EPe-==
s
2
s
3          (13) 
where E is obtained from the solution of Eq. (12) at t = 0 
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After the initial stage, the Donnan equilibrium defines the relationship between 
the surface concentrations, Eq. (8) can be rewritten as 
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 The electroneutrality condition yyy s3
s
2
s
1 -=  can now be used and Eq. (15) 
is now written as 
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 Mass balances for the drug and Na+ ions, i = 1 and 3, inside the membrane need to 
be considered to evaluate the time dependence of concentrations 
AJ
t
n
i
i
d
d
=-           (17) 
where ii cVn = now the time scale is changed to the amount of the salt introduced to the 
cell, to compare different convection rates V
·
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Eq. (17) is then rewritten for the cations 
0
1
salt
1
d
d
nPe
j
n
y d
=-          (19 a) 
0
3
salt
3
2d
d
nPe
j
n
y d
=-          (19 b) 
and outside the membrane 
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The following iterative procedure is employed  
Step 1: E is calculated from Eq. (14) 
Step 2: Insert the initial values of all the quantities as old values to obtain the new ones 
by means of the following expressions (taking salt increments D nsalt): 
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Step 3: Solve Eq. (12) numerically using the new values of the concentrations obtained in 
step 2 to obtain the new value of E. 
Step 4: Go to step 2 for the next salt increment inserting all these calculated values as old 
values. n0 and 0n  are always taken as 1.  
In all cases the Peclet number was the main fitting parameter, whereas the 
partition coefficient K was not allowed to change for a given pair of drug species and ion-
exchange material. From the results (figure 2) it was clear that the release rate of tacrine 
was much higher from the staple fiber than from the cloth and even greater than from the 
gel or the resin. This trend was the same for all the model drugs. 
As the flow of electrolyte solution was increased, the drug release rate and extent 
usually increased accordingly. Only tacrine showed different behaviour, since when the 
flow rate was changed from 1.0 cm3min-1 to 5.0 cm3min-1 the release rate of tacrine did 
not increase. An explanation for this was that possible ion-exchange kinetics started to 
affect the release of tacrine. 
The release rates of tacrine from the fibers, as noted earlier (II), and from the 
other ion-exchange matrices were slower than the release rates of the rest of the model 
drugs with the same flow rate. This was due to the strong interaction between tacrine and 
the ion-exchange materials. The difference in the structure of tacrine and the other model 
drugs is that tacrine does not contain any bulky or flexible substituents. The calculuated 
van der Waals volumes for nadolol, propranolol and tacrine were, 275, 245 and 160 Å3 
respectively.105 Comparing these values may help to visualise the bulkiness of 
substituents. 
This study also showed again that the release rates from the fiber were higher for 
the hydrophilic drugs than for the lipophilic drugs. It was also clear that all the model 
drugs had higher release rates from the fibers than from the resin or the gel and that the 
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difference in release rates between the fiber or the gel/resin was greater for more 
lipophilic drugs. The difference in release rates between the fiber and the resin or the gel 
can be explained by an increase in surface area of the ion-exchange matrix and/or a 
decrease in the diffusion layer thickness, which allows the rapid access of ions to the ion-
exchange groups.106, 107 
The small differences between the model and the experimental results can be 
explained by the nonspecific adsorption of chloride ions to the fiber or drug adsorption on 
the ion-exchange matrix or onto the side chains of the bound drugs.6, 108 
 
a)       b) 
 
c)       d) 
Figure 2. Experimental (o , ×, à , +, ¨¨ stand for staple 101, staple 102, cloth 102, gel and resin, 
respectively) and theoretical (solid lines) fractions of drug released as a function of the amount of 
Na+flowed through the cell at a flow rate of 5.0 cm3min-1 for, a) tacrine b) propranolol c) metoprolol and d) 
nadolol. Parameters used in modeling can be found in paper IV. 
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4.3 An iontophoretic study  
4.3.1 Iontophoresis in vitro (I, V) 
4.3.1.1 Iontophoresis using a side-by-side cell (I) 
The model drugs in this paper were tacrine (-HCl), nadolol, propranolol (-HCl) 
and sodium salicylate. The ion-exchange fibers were Smopex®-102 (-COOH) and -108 (-
NH2), in the woven form. 
In this paper the transdermal delivery of model drugs was assessed using 
transdermal iontophoresis. Charged model drugs were complexed with anion and cation-
exchange fibers as reservoirs for controlled drug delivery. Also, the iontophoretic drug 
delivery from the ion-exchange fiber were compared to the iontophoretic delivery from 
solution formulations. 
A side-by-side cell (described in 2.2.1.) was used to test the release of the drugs 
from the ion-exchange fibers or from a 5 w-% drug solution across cadaver skin samples 
into a physiological saline solution. Drug concentrations were determined by HPLC. 
In vitro drug permeation from a 5 w-%  solution across human skin was 
investigated under both passive and iontophoretic (I = 0.5 mAcm-2) conditions. The 
results are presented in table 7. The differences in the values of passive flux are evidently 
related to the chemical characteristics of the drug. The lipophilic drugs (tacrine, 
propranolol and salicylate) had considerably higher permeation rate than the more 
hydrophilic nadolol. Iontophoresis enhanced the transdermal permeation for all of the 
drugs but it was much larger for nadolol (enhancement factor Ei,e = 1200) than for the 
lipophilic drugs, which has also been detected earlier.95 Tacrine which had the highest 
passive permeation rate, also had the lowest enhancement factor. 
The flux of tacrine through the skin from the solution was also studied as a 
function of the current density (I = 0, 0.10, 0.25 and 0.5 mAcm-2). In all cases the 
iontophoretic permeation rate remained constant until the current was switched off, after 
which the permeation rate returned to the passive level. The value of the permeation rate 
was directly proportional to the iontophoretic current density used, in accordance with 
earlier studies.6, 109-111 
The release rate from the fiber was dependent on the lipophilicity of the drug. The 
release rates of the lipophilic drugs tacrine and propranalol were significantly lower than 
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that of the more hydrophilic nadolol. Anion-exchange fiber 108 was tested using anionic 
sodium salicylate. The iontophoretic flux enhancement of salicylate ions across the skin 
due to the fibers was substantial. (See table 7.) 
Since the drug content in the fiber experiment was lower than that in the solution 
experiment (e.g. for the 5 w-% solution), and the drug had also to be released from the 
ion-exchange fibers before permeating across the skin, then the drug flux from the fibers 
was clearly lower than the flux of the drug in solution. (See table 7.) 
 
Table 7. In vitro passive and iontophoretic fluxes (µgcm-2h-1 ) and enhancement factors across human skin 
from a 5 % (w-%) solution and from a cation-exchange fiber SmopexÒ-102 or anion-exchange fiber 
SmopexÒ-108. Direct current iontophoresis (0.5 mAcm-2) for 12 hours. Average ± standard deviation (N=4-
7.) 
Drug Passive flux 
(solution) 
Iontophoretic flux 
(solution) 
Enhacement factor 
(solution) 
Iontophoretic flux 
(fiber) 
Tacrine 3.00 ± 0.70 220 ± 50 70 4.1 ± 0.7 
Propranolol 0.26 ± 0.07 43 ± 7 170 27.0 ± 6.0 
Nadolol 0.04 ± 0.05 49 ± 7 1200 10.5 ± 1.3 
Sodium 
salicylate 
0.34 ± 0.07 45 ± 6 130 28.0 ± 5.0 
 
The iontophoretic flux of tacrine across skin was also investigated as a function of 
the amount of drug in the fiber (in the range 7.6 to 104.0 mg of tacrine). It was observed 
that the flux increased with increasing concentration, however, the increase was non-
linear at the end of the scale. One possible reason could be a limiting mechanism of the 
skin at higher drug concentrations.6 Alternatively, the electrodiffusion process under 
consideration involves an electric field determined by differences in permeabilities of the 
three transferring species, as well as the current density. In paper I the iontophoretic flux  
of this system was modeled and the simulation showed a non-linear behaviour similar to 
that observed experimentally. 
 
4.3.1.2. Iontophoresis using a in-house designed test cell (V)  
 The ion-exchange fiber material employed was Smopexâ-102 in the staple form. 
The cationic model drugs were tacrine (-hydrochloride) and metoprolol (-tartrate). 
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Ag/AgCl electrodes were used in all experiments. Nafion® 90209, (ElectroCell AB, 
Sweden) soaked for at least 24 hours in a 1.5 M NaCl solution before use, was used in the 
test cell between the anode and the fiber compartment. Hydrophilic Ultracel Amicon 
PLAC (regenerated cellulose) NMWL (nominal molecular weight limit): 1000 
ultrafiltration membranes (Millipore Co., U.S.A.) were placed between the fiber and the 
cathode compartment. 
 The amount of the drug containing ion-exchange material to be used in the 
experiments was calculated and weighed so that each sample contained the same mass of 
the drug (60 mg). Tacrine concentration in the fiber was 2.8 mmolg-1 and metoprolol 
concentration was 1.7 mmolg-1. The ion-exchange material under analysis was placed 
inside the cell (figure 1). The NaCl solution (V = 4 cm3, 0.15, 0.30 or 0.50 M) was 
injected into the fiber compartment, 30 cm3 of the same salt solution was added to the 
cathode (receiver) compartment and 3 cm3 of 1.5 M NaCl was added into the anode 
compartment. 
A constant direct current of 0.05, 0.10, 0.25 and 0.50 mAcm-2 was applied for 
every salt concentration in room temperature for 8 h. Samples (500 µl) were collected 
from the cathode chamber in fixed intervals and replaced by fresh salt solution. The 
passive diffusion experiments were done the same way as the iontophoretic experiment, 
but no current was applied, samples were taken after 2, 4, 8 and 24 h. Drug 
concentrations were analyzed by HPLC. 
 It was shown that the release rate of tacrine was enhanced with increasing NaCl 
concentration and increasing current density until the limiting current value was reached. 
Also, the effect of the amount of drug loaded into the fibers versus the amount of drug 
released was investigated. It was clear that when a certain maximum drug concentration 
was used in the fibers, the amount of released reached a maximum, and with increasing 
amount of drug loaded the amount of drug released remained constant, which was also 
detected earlier.I 
From the release profiles of tacrine it was observed that the release followed first 
order kinetics, which could be achieved from a source of constant concentration to a sink. 
Then the flux is given by 
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J = Kpc ;  Kp » Deff / h (21) 
 
where Kp is the permeability coefficient, Deff is the effective diffusion coefficient of the 
drug, including porosity and tortuosity factors in the membrane and h is the membrane 
thickness. Since the membrane is rather porous, Deff is of the same order of magnitude as 
the diffusion coefficient of tacrine in water, ca. 7´10-6 cm2s-1.112 The membrane 
thickness is of the order of 250 µm, making Kp »  3´10-4 cms-1, but a conservative 
estimate Kp = 10-4 cm s-1 is used. The passive flux (I = 0) for [NaCl] = 0.15 M is 2.5 
µgcm-2h-1 ( »  0.7 ngcm-2s-1), which means that the concentration of free tacrine in the 
fiber chamber is only in the order of 7 µgcm-3. As the chamber volume is 4 cm3, only ca. 
30 ng of tacrine is present in the free volume of the fiber chamber, in contrast to the 
loading of the fiber, ca. 60 mg of tacrine. The equilibrium of tacrine between the aqueous 
phase and the fiber is strongly on the fiber side. 
For the pure ion exchange mechanism the (formal) equilibrium constant K of the 
ion-exchange reaction (Ch 4.1.1.) would be 
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where the overbar denotes the fiber and x is the amount of tacrine (in moles) released 
from the fiber; the latter approximation holds as x « n,n
0
Na
0
d , the initial amounts of tacrine 
and NaCl, respectively. Therefore, doubling the NaCl concentration would increase x and 
the flux by the factor of 2 »  1.4. the ratios of the fluxes is 1 : 1.7 : 2.7, in contrast to 
the expected ratios 1 : 1.4 : 2.2 (1 : 2  : 5 ) (results shown in paper V). Thus, it is 
clear that the ion exchange mechanism is not solely responsible for the release of tacrine, 
but nonspecific adsorption also takes place on the fiber, as shown in paper IV. 
 The first way to analyze the data is to compare the flux of tacrine with the electric 
current density via its apparent transport number tapp =(FJ / I). Using the data from paper 
V tapp = 0.04 in all cases, which means that tacrine is a trace ion in the transport process, 
i.e. its contribution to the total conductivity of the membrane is insignificant. In such a 
case, the Goldmann constant field approximation applies and the flux can be estimated by 
the relation 
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where Ei,e is the iontophoretic enhancement factor. The potential drop, fD , can be 
obtained from the ratio of the passive and iontophoretic fluxes. 
 Considering, for example, the case where I = 0.25 mAcm-2 , [NaCl] = 0.15 M, and 
fD = 143 mV, then the potential drop is purely ohmic: 
k
f
IL
=D  (24) 
 In Eq. (24), L is the length over which the potential drop is effective and k  is the 
conductivity of the system within L. The conductivity of 0.15 M NaCl solution is ca. 15 
mS cm-1. Hence, L = fDk /I »  8.5 cm, so it can be deduced that potential drop does not 
occur solely across the membrane, but across the length between the electrodes. This 
result is, however, expected, because the membrane is so porous and thin that its 
resistance does not contribute to the total cell resistance significantly. 
 fD  increases as the current density increases, agreeing with Eq. (24). More 
problematic is that fD  increases also with the increasing NaCl concentration, although 
the conductivity increases as well, thus conflicting with Eq. (24). A possible explanation 
is that as the electric field is operative also within the stack of fibers, it affects the 
partition equilibrium between the fiber and its bathing solution. The potential drop was 
calculated assuming implicitly that the concentration of the donor solution remains 
constant, but if the electric field enhances the release of tacrine from the fiber, then fD  
was overestimated.  
 A more relevant question is if the delivery system presented here can provide 
release rates high enough to achieve the therapeutic level. The mass balance can be 
written as follows: 
cCLJAkVcJA
t
n
kc
V
JA
t
c
-=-=Û-=
d
d
d
d  (25) 
In Eq. (25), c is the drug concentration in plasma, V the distribution volume, k the first 
order metabolic rate constant, and CL is the clearance. At steady state dn/dt = 0, and 
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J
cCL
A =  (26) 
 The clearance of tacrine is 150 dm3h-1 and the therapeutic level is 5-30 µgdm-3.113 
Taking, for example J = 25 µgcm-2h-1 then the required area of the device A = 30-180 cm2 
which can be uptained by using circular patches with a diameter in the range 6-15 cm.
 Metoprolol has significantly different release properties to tacrine and was chosen 
as a second example drug due to its rapid release from the SmopexÒ-102 fiber.II, IV Only 
when using the most dilute salt concentration was there some discernable difference 
between passive diffusion and iontophoretic transport. When using higher salt 
concentrations the diffusion of metoprolol was so high that it was impossible to control 
the release rate by varying the current density. 
 Iontophoresis of tacrine in a solution did not show any maximum limiting current 
values in our earlier studies.I Therefore, we also tested for possible electrode reactions or 
drug adsorption to the electrodes. Cyclic voltammetry did not show any evidence of drug 
decomposition on the electrodes, but tests of adsorption showed that the tacrine 
concentration in the cathode compartment decreased with time and the decrease in 
concentration was further increased with current density. 
 Comparing the release rate values of metoprolol to the release rate of tacrine at 
the same salt concentration and current density, shows that the release rates of metoprolol 
were an order of magnitude higher than the corresponding release rates of tacrine. The 
differences between the release rates did, however, decrease when the current density was 
increased. Our earlier studies already established that metoprolol is released from the 
fibers substantially faster than tacrineIV and that the release of tacrine from several types 
of ion-exchange fiber is slower compared to other drugs.I, II Also, it was established that 
tacrine was adsorbed on the electrode surfaces, which was not detected in the case of 
metoprolol. 
 
4.3.2 Iontophoresis in vivo (III) 
Here iontophoresis was used in vivo on ten healthy adult volunteers to investigate 
whether therapeutically relevant concentrations of tacrine could be achieved in the blood 
stream. The clinically relevant steady state level of tacrine after oral intake is 5-30 ng per 
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cm3 of blood plasma.113 In-house made ion-exchange fiber (woven form) electrodes and 
commercial Iogel®-electrodes were used, in both experiments a battery (9V) operated 
constant current source Phoresor® II Auto was used. The structure of the ion-exchange 
fiber electrodes is presented in figure 3. 
Tacrine formulations were applied to the forearms of ten healthy adult subjects 
with three hours of current delivery (0.4 mAcm-2), after which passive tacrine flux 
followed for one hour. The position of the electrodes was changed three times during the 
experiment. Blood samples were withdrawn after 30, 60, 90, 120, 150, 180 and 240 min. 
Plasma concentrations of the drug were determined by HPLC. 
The alanine aminotransferase (ALT) level of the volunteers was determined 
before and after the experiments. The value had to be = 50 Ul-1 before acceptance for the 
test. After the experiment the ALT levels of the volunteers was found to be below the 
limit mentioned above. 
 
Figure 3. Schematic representation of the in-house designed ion-exchange fiber electrodes (modified from 
III). 
The iontophoretic delivery of tacrine resulted in therapeutically significant plasma 
concentrations in all of the experiments using both the gel and ion-exchange devices. The 
average tacrine in vivo plasma concentrations were 21.3 ngcm-3 and 14.9 ngcm-3, 
respectively (figure 4). Constant plasma concentrations of tacrine were achieved within 
30 min with both patch formulations. The passive permeation period of one hour did not 
have a great effect on the plasma concentrations, but only a small decrease was detected. 
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This is possibly due to the lipophilicity of tacrine which allows it to bind into the 
lipophilic skin structures and then release slowly to systemic circulation. 
As one of the problems with gel type transdermal iontophoresis is the inter- and 
intrasubject variability, it was hoped that ion-exchange fibers would show less variable 
results. However, in the case of tacrine, even though the standard deviations during the 
test II (fiber) were slightly smaller than during test I (gel), the difference was not 
statistically significant. 
 
 
Figure 4. Plasma concentrations (average ± SD) of tacrine as a function of time. Test I, Iogel- electrodes 
(N=10) (nn) and test II, ion-exchange fiber electrodes (N=9) (· ). To distinguish the test I and II, the 
curve of the former has been transformed forward by 5 min. Dashed horizontal lines express the upper and 
lower limits of the therapeutic range. [Modified from III] 
 
Adverse skin reactions, either due to iontophoresis or to the drug, were monitored. 
Transient skin irritation reactions which occurred included pinching or prickling 
sensations, erythema, drying of the skin and coldness of the skin and fingertips. Skin 
irritation reactions correlated directly with the current density and the duration of the 
current application, however, none of the adverse effects were regarded as serious. The 
possible irritating effect of the tacrine (without application of current) and iontophoresis 
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(0.1 - 0.4 mAcm-2, without tacrine) was also tested on five volunteers. No additional 
erythema on the skin was attributed to the use of tacrine in these short experiments. All of 
the side effects caused by the iontophoresis were similar to those reputed elsewhere.40, 114, 
115 
After this short term test all the values of ALT on test subjects were under the 
normal range. Naturally, to determine the possible effects of long-term delivery of tacrine 
on the liver function more trials are needed. However, the liver toxicity of tacrine is 
expected to be lower transdermally than by oral administration due to the decreased first-
pass metabolism. 
 
4.3.3 In vivo / in vitro correlation of tacrine permeation from the test 
formulations (III) 
 The in vitro experiments were performed using Franz type diffusion cells (the 
bottom half, the upper half was replaced with a patch formulation). The excised human 
epidermis was placed between the patch formulation and the receiver compartment, 
which was filled with HEPES buffered physiological NaCl. 200 µl samples were 
collected from the receiver compartment and replaced by fresh buffer at 30, 60, 90, 120, 
150, 180 (current off) and 240 min. The surface area of the skin was 2.41 cm2. The 
current source was Phoresor® II Auto, the same equipment that was used in the in vivo 
experiments. The patch formulation acted as the anode and a Ag/AgCl electrode was 
placed in the receiver compartment as the cathode. 
 The in vitro steady state fluxes of tacrine JSS, µgmin-1cm-2 were calculated from 
the linear part of the permeation curves by linear regression. The predicted in vivo plasma 
levels were calculated using Eq. (27)1 
CL
AJ
c SSSS =           (27) 
where cSS (ngcm-3) is steady state plasma concentration, A is the area for drug absorption 
and CL (dm3h-1) is the pharmacokinetic clearance of the drug from the body, for tacrine 
CL is 150 dm3h-1.113 The area of the devices was related to 10 cm2. 
 From table 8 it can be seen that the correlation between the in vitro and in vivo 
data was very good for the gel formulation. However, in the case of the ion-exchange 
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fiber formulation the in vitro data predicted a significantly smaller flux than the measured 
in vivo drug delivery. 
  
Table 8. Steady state concentrations (cSS/ ngcm-3) of tacrine in human plasma based on in vitro (calculated) 
and in vivo experiments. The iontophoretic current density was 0.4 mAcm-2 for 3 h. 
Formulation In vitro cSS / ng
 cm-3 In vivo cSS / ng
 cm-3 
Test I 
Iogel® formulation 
22.4 ± 5.3 21.3 ± 5.9 
Test II 
Ion-exchange fiber formulation 
0.43 ± 0.19 14.9 ± 2.6 
 
The correlation between the in vitro and in vivo seems to be dependant on the 
experimental conditions, the individual skin source and the drug in question, since the 
results from several research groups vary significantly. 23, 83, 114, 116-118 Phipps and 
Gyory,116 for instance observed that the in vivo concentration was generally higher than 
the in vitro concentration, whereas Van der Geest et al.114 obtained the opposite result. 
Therefore, further studies are needed to solve the reasons for the poor correlation between 
in vivo and in vitro experiments. 
 
5. Conclusions 
Studies with ion-exchange fibers showed that they are promising materials for 
transdermal iontophoretic drug delivery systems. According to these studies, when the 
lipophilicity of the drug is known, the most suitable ion-exchange fiber can be estimated.  
From the in vitro tests it can be seen that tacrine release can be controlled by the 
device and that tacrine is a suitable candidate for this kind of iontophoretic transdermal 
drug delivery system. Metoprolol, however, needs a system where the release rate from 
the device is lower. This can be achieved for instance by using more dilute salt 
concentration or using different ion-exchange matrix. The test cell designed for screening 
suitable systems for transdermal iontophoresis although applicable needs further refining, 
e.g. the Ag/AgCl electrode in the sample compartment should be covered to prevent 
possible drug adsorption. 
The transdermal iontophoretic patch system used in the clinical trial was at an 
early stage of development, however, still proved to be functional. Thus, transdermal 
iontophoresis can be utilized to deliver clinically relevant plasma concentrations of 
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tacrine at the expense of minor irritation of the skin. Also, since the drug plasma 
concentrations in the blood were higher than the therapeutic concentration, it is possible 
to use a lower or an intermittent current density and still reach a clinically relevant 
concentration and reduce the adverse effects of iontophoresis. 
The final construction of the iontophoretic patch and the optimization of 
materials, such as membranes and electrode materials, are still under consideration. 
Especially, the use of porous cation-exchange membranes instead of PLAC could 
increase the control over the amount of drug released by the current density and salt 
concentration.  
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List of abbreviations  
 
ALT   alanine aminotransferase 
CMC   carboxymethyl cellulose sodium 
DC direct current 
GHRP growth hormone-releasing peptide (L-histidyl-D- tryptophyl -L-
alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide) 
HEPES  N-2-hydroxyethylpiperazine-N-2-ethanesulphonic acid 
HPC   hydroxypropylcellulose 
HPLC   high performance liquid chromatography 
HPMC   hydroxypropyl methyl cellulose 
NMWL  nominal molecular weight limit 
PAA   polyacrylamide 
PLAC   Millipore ultrafiltration membrane 
PVA   polyvinyl alcohol 
PVP   polyvinylpyrrolidine 
RDS   rate determining step 
SC   stratum corneum 
Smopex®-101  poly(ethylene-g-styrene sulfonic acid) fiber 
Smopex®-102  poly(ethylene-g-acrylic acid) fiber 
Smopex®-107  poly(ethylene-g-acrylicacid-co-vinyl sulphonic acid) fiber 
Smopex®-108  amidoxime functional fiber 
SNA   sodium nonivamide acetate 
SNP    sodium nonivamide propionate 
 
 
List of symbols 
 
A   area for drug absorption 
A    effective surface area 
c   concentration 
CL   clearance 
Deff   effective diffusion coefficient 
Di   diffusion coefficient of i 
E   electric field 
Ei,e   iontophoretic enhancement factor  
F   Faraday constant 
h   membrane thickness 
I   current density 
J   molar flux density 
k   first order metabolic rate constant 
Kc   chemical partition coefficient 
Ke   electrical partition coefficient 
Kp   permeability coefficient 
L   length over which the potential drop is effective 
N   number of experiments 
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P   partition coefficient 
Pe   Peclet number 
R   gas constant 
T   thermodynamic temperature 
tapp   apparent transport number  
u   convective velocity of the solution 
V   volume 
·
V    volume flow 
x   perpendicular distance from the fiber surface 
zi   charge number of species i 
d    diffusion boundary layer thickness 
k    conductivity 
m0    standard chemical potential 
fD    Donnan potential 
fD  potential drop 
 
 
Superscripts: 
   
b    bulk aqueous phase 
s    interface 
overbar   fiber phase 
0   initial stage 
 
Subscripts: 
    
d    drug 
+    cation 
-   anion 
m   ion-exchange groups bound to the fiber  
SS   steady state  
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